drugs Archives - MyMedicPlus

Anti-Aging Drugs Market to see Huge Growth by 2025 | BioTime, Elysium Health, Estee Lauder

mymedicplus — Mon, 30 Nov 2020 07:21:04 +0000

Source – https://cheshire.media/

Anti-Aging Drugs Market Analysis, Anti-Aging Drugs Market Covid 19 impact, Anti-Aging Drugs Market Forecast, Anti-Aging Drugs Market Growth, Anti-Aging Drugs Market opportunity, Anti-Aging Drugs Market share, Anti-Aging Drugs Market size, Anti-Aging Drugs Market Trends, Covid Outbreak Anti-Aging Drugs Market

Anti-Aging Drugs Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Anti-Aging Drugs industry with an attention on the Global market. The report gives key insights available status of the Anti-Aging Drugs producers and is an important wellspring of direction and course for organizations and people keen on the business. By and large, the report gives an inside and out understanding of 2020-2025 worldwide Anti-Aging Drugs Market covering extremely significant parameters.

Key Players in This Report Include,

Nu Skin Enterprises (United States),Novartis AG (Switzerland),BioTime Inc. (United States),ARK Skincare (United Kingdom),Elysium Health Inc. (United States),Estee Lauder Inc. (United States),DermaFix (South Africa),Bayer Pharma AG (Germany),La Roche-Posay (United States),L’Oreal SA (France)

Brief Summary of Anti-Aging Drugs:

Anti-aging drugs are generally used to slow down or reverse the process of aging aiming to extend the healthy lifespan. It is the combination of advanced biotechnology and clinical preventing medicines which is used for prevention and treatment of age associated disorders and diseases. Further, many medical technologies are being developed in order to delay the aging process. Also, the advancements in medical science and rising health consciousness among people are the key factors boosting the market growth.

Market Trend

Primitive desire of people to remain young

Restraints

Stringent regulations and definition ambiguity

Opportunities

New advanced technologies and cellular understanding

The Global Anti-Aging Drugs Market segments and Market Data Break Down are illuminated below:

by Application (Skin and Hair, Skeletal and Muscles, Age Related Disorders, Others), Therapy (Homeopathic, Allopathic), Drug Class (Serums and Supplement, Antioxidants and Enzymes, Stem Cells, Drugs)

This research report represents a 360-degree overview of the competitive landscape of the Global Anti-Aging Drugs Market. Furthermore, it offers massive data relating to recent trends, technological, advancements, tools, and methodologies. The research report analyzes the Global Anti-Aging Drugs Market in a detailed and concise manner for better insights into the businesses.

Regions Covered in the Anti-Aging Drugs Market:

The Middle East and Africa (South Africa, Saudi Arabia, UAE, Israel, Egypt, etc.)
North America (United States, Mexico & Canada)
South America (Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, etc.)
Europe (Turkey, Spain, Turkey, Netherlands Denmark, Belgium, Switzerland, Germany, Russia UK, Italy, France, etc.)
Asia-Pacific (Taiwan, Hong Kong, Singapore, Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia).

The research study has taken the help of graphical presentation techniques such as infographics, charts, tables, and pictures. It provides guidelines for both established players and new entrants in the Global Anti-Aging Drugs Market.

The detailed elaboration of the Global Anti-Aging Drugs Market has been provided by applying industry analysis techniques such as SWOT and Porter’s five-technique. Collectively, this research report offers a reliable evaluation of the global market to present the overall framework of businesses.

Attractions of the Anti-Aging Drugs Market Report:

The report provides granular level information about the market size, regional market share, historic market (2014-2018) and forecast (2019-2025)
The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
The report tracks recent innovations, key developments and start-up’s details that are actively working in the market
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Key Points Covered in the Table of Content:

Chapter 1 to explain Introduction, market review, market risk and opportunities, market driving force, product scope of Anti-Aging Drugs Market;

Chapter 2 to inspect the leading manufacturers (Cost Structure, Raw Material) with sales Analysis, revenue Analysis, and price Analysis of Anti-Aging Drugs Market;

Chapter 3 to show the focused circumstance among the best producers, with deals, income, and Anti-Aging Drugs market share 2020;

Chapter 4 to display the regional analysis of Global Anti-Aging Drugs Market with revenue and sales of an industry, from 2020 to 2022;

Chapter 5, 6, 7 to analyze the key countries (United States, China, Europe, Japan, Korea & Taiwan), with sales, revenue and market share in key regions;

Chapter 8 and 9 to exhibit International and Regional Marketing Type Analysis, Supply Chain Analysis, Trade Type Analysis;

Chapter 10 and 11 to analyze the market by product type and application/end users (industry sales, share, and growth rate) from 2020 to 2026

Chapter 12 to show Anti-Aging Drugs Market forecast by regions, forecast by type and forecast by application with revenue and sales, from 2020 to 2025;

Chapter 13, 14 & 15 to specify Research Findings and Conclusion, Appendix, methodology and data source of Anti-Aging Drugs market buyers, merchants, dealers, sales channel.

Anti-Aging Drugs Market research provides answers to the following key questions:

What is the expected growth rate of the Anti-Aging Drugs Market?
What will be the Anti-Aging Drugs Market size for the forecast period, 2020 – 2026?
What are the main driving forces responsible for changing the Anti-Aging Drugs Market trajectory?
Who are the big suppliers that dominate the Anti-Aging Drugs Market across different regions? Which are their wins to stay ahead in the competition?
What are the Anti-Aging Drugs Market trends business owners can rely upon in the coming years?
What are the threats and challenges expected to restrict the progress of the Anti-Aging Drugs Market across different countries?

About Author:

Advance Market Analytics is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies’ revenues.

Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enable clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As.

The post Anti-Aging Drugs Market to see Huge Growth by 2025 | BioTime, Elysium Health, Estee Lauder appeared first on MyMedicPlus.

Cardiovascular Drugs Market Report, 2019-2026 | Growth, Trends and Forecast

mymedicplus — Sat, 28 Nov 2020 06:42:37 +0000

Source – https://cheshire.media/

Cardiovascular Drugs Industry, Cardiovascular Drugs Industry Report, Cardiovascular Drugs Market, Cardiovascular Drugs Market Demand, Cardiovascular Drugs Market Developments, Cardiovascular Drugs Market Dynamics, Cardiovascular Drugs Market Factors, Cardiovascular Drugs Market forecast, Cardiovascular Drugs Market Growth”, Cardiovascular Drugs Market Manufacturers, Cardiovascular Drugs Market players, Cardiovascular Drugs Market Report, Cardiovascular Drugs Market Segments, Cardiovascular Drugs Market share, Cardiovascular Drugs Market size, Cardiovascular Drugs Market trends, Coronavirus Outbreak on Cardiovascular Drugs Market, COVID-19 Impact On Cardiovascular Drugs Market, COVID-19 Outbreak on Cardiovascular Drugs Market, Impact of Coronavirus on Cardiovascular Drugs Market, Impact of COVID-19 On Cardiovascular Drugs Market, Impact of COVID-19 Outbreak on Cardiovascular Drugs Market

Cardiovascular Drugs Market Report has recently added by Value Market Research, this surveillance report establishing the facts based on current scenarios, historical records from 2019 to future forecast up to 2026. This report explicit data of various outlooks such as market share, size, growth rates, and industry opportunities and offering an economical advantage for business success. It furnishes a 360-degree overview of the competitive landscape of the global industries. Porter’s Five Forces Model analysis has been used to understand the industry’s structure, strength, weaknesses, opportunities, threats and challenges in front of the businesses. Moreover, the report also highlights a sudden occurrence of COVID-19 impact on the cardiovascular drugs market to improve future capacities and other developments.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cardiovascular drugs market include Pfizer, Inc., AstraZeneca plc, Merck & Co., Sanofi S.A., Novartis AG, Daiichi Sankyo Company Limited, Takeda Pharmaceutical Company Limited, and Bayer AG. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

Market Dynamics

The driving force for the cardiovascular drug market is the increase in awareness about the effects of these medications. This is resulting in boosted demands for CVD drugs, demands that are reinforced by poor air quality, an increasingly sedentary lifestyle, and rising levels of social unrest. However, cardiovascular diseases carry a heavy economic burden, which acts as a grave challenge for the cardiovascular drug market. With the increase in aging popular across the globe, there is a considerable need for innovation and development of new drugs, thereby generating lucrative business prospects for the manufacturers. The progress of regenerative medicine as an emerging field of scientific research is foreseen to drive the CVC market.

The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.

Additionally, these tools also give inclusive assessment of each application/product segment in the global market of cardiovascular drugs.

Market Segmentation

The entire cardiovascular drugs market has been sub-categorized into disease, drug class and distribution channel. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.

By Disease

Cardiac Arrhythmias
Arteriosclerosis
Acute Coronary Syndrome
Myocardial Infarction
Coronary Artery Disease
Peripheral Artery Disease
Hyperlipidaemia
Hypertension
Cardiac Failure Diseases
Thrombosis
Others

By Drug Class

Anti-Hyperlipidemics
Anti-Fibrinolytic
Anti-Hypertensive
Anti-Arrhythmic
Anti-Coagulants
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Regional Analysis

This section covers regional segmentation which accentuates on current and future demand for cardiovascular drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.

About Us:

Value Market Research was established with the vision to ease decision making and empower the strategists by providing them with holistic market information.

We facilitate clients with syndicate research reports and customized research reports on 25+ industries with global as well as regional coverage.

The post Cardiovascular Drugs Market Report, 2019-2026 | Growth, Trends and Forecast appeared first on MyMedicPlus.

IIT develops low-cost tech to produce psychoactive drugs, anti-aging compounds from agri resources

mymedicplus — Wed, 28 Oct 2020 06:02:41 +0000

Source – https://www.hindustantimes.com/

The technology which has been patented and developed by Mihir Kumar Purkait, Head, Centre for the Environment and Professor, Department of Chemical Engineering, IIT Guwahati along with his M Tech student V L Dhadge, does not use any organic solvents.

Researchers at the Indian Institute of Technology (IIT), Guwahati, have developed a low-cost membrane technology to produce psychoactive drugs and anti-aging compounds from wide range of agricultural resources like citrus fruits and peels especially orange peels, berries, parsley, pulses, tea, sea buckthorn and onions.

The technology which has been patented and developed by Mihir Kumar Purkait, Head, Centre for the Environment and Professor, Department of Chemical Engineering, IIT Guwahati along with his M Tech student V L Dhadge, does not use any organic solvents.

“The health-related beneﬁts of psychoactive drugs (caffeine) and anti-aging compounds (ﬂavonoids) attributed to stimulating detoxiﬁcation of enzyme activity and inhibition of cell invasion and angiogenesis. Because of medicinal applications, ﬂavonoid components have gained popularity as ingredients in pharmaceutical industry. These are also found in smaller amount in bamboo leaves, grapes, apples, and other natural sources,” said Purkait.

“The developed technology is exclusively pore and particle size based pressure driven membrane separation process. The water extracts of the plants, fruits or leaves at optimum operating conditions are passed through a specially made cascade membrane units of fabricated with appropriate molecular weight cut off (MWCO) membranes capable of separating targeted flavonoids selectively,” he added.

The permeate and retentive part from appropriate membrane unit is then fridge dried to get the powdered product. “We have synthesized stimuli responsive smart membrane for the selective separation and purification of targeted compound from the mixture of plants or leaves or fruits extract in simple water,” he further said.

The professor explained that the commercially available techniques are using various costly organic solvents like Chloroform, Acetone, Acetonitrile, among others and as a result the price of these important pharmaceutical raw materials are quite high that ultimately increases the price of the antioxidant. “Since organic solvents are used, the technology suffers various disadvantages like low product quality and yield, high operating and product cost, more time consuming and high energy intensive process for solvent recovery and has limitation to run continuation mode in industrial scale. “The technology developed by us doesn’t require any costly organic solvents and uses only water. Hence, the cost of the process and price of pharmaceuticals thereon is much cheaper than that of existing solvent based separation technique. The patented membrane based green technology has enormous scope to replace existing costly organic solvent based techniques and can be used for continuation mode of operation in industrial scale,” he said.

The post IIT develops low-cost tech to produce psychoactive drugs, anti-aging compounds from agri resources appeared first on MyMedicPlus.

How anti-ageing drugs could boost COVID vaccines in older people

mymedicplus — Fri, 16 Oct 2020 06:10:46 +0000

Source – https://www.nature.com/

COVID-19 poses the greatest threat to older people, but vaccines often don’t work well in this group. Scientists hope drugs that rejuvenate the immune system will help.

Unlike fine wine, the human body does not improve with age. Hearing fades, skin sags, joints give out. Even the body’s immune system loses some of its vigour.

This phenomenon, known as immunosenescence, might explain why older age groups are so hard-hit by COVID-19. And there is another troubling implication: vaccines, which incite the immune system to fight off invaders, often perform poorly in older people. The best strategy for quelling the pandemic might fail in exactly the group that needs it most.

Scientists have known for decades that ageing immune systems can leave the body prone to infection and weaken their response to vaccines. In June, the US Food and Drug Administration announced that a COVID-19 vaccine would have to protect at least half the vaccinated individuals to be considered effective, but protection in older adults might not even meet that bar. “No vaccine is going to be as effective in the elderly as it is in young people,” says Matt Kaeberlein, a gerontologist at the University of Washington in Seattle. “That’s an almost certainty.”

The human immune system is mind-bendingly complex, and ageing affects nearly every component. Some types of immune cell become depleted: for example, older adults have fewer naive T cells that respond to new invaders, and fewer B cells, which produce antibodies that latch on to invading pathogens and target them for destruction. Older people also tend to experience chronic, low-grade inflammation, a phenomenon known as inflammageing (see ‘Depleted defences’). Although some inflammation is a key part of a healthy immune response, this constant buzz of internal activation makes the immune system less responsive to external insults. “This overarching, chronic inflammatory state is what’s driving much of the immune dysfunction that we see,” says Kaeberlein. The upshot is a poorer reaction to infections and a dulled response to vaccines, which work by priming the immune system to fight off a pathogen without actually causing disease.

With about 50 COVID-19 vaccine candidates currently being tested in humans, researchers say it’s not yet clear how they will fare in older adults. In its phase I study of 40 people aged 56 and over, Moderna in Cambridge, Massachusetts, reported that its candidate mRNA-1273 elicited similar antibody levels as those elicited in a younger age group¹. The Chinese biotech Sinovac in Beijing, which trialled its CoronaVac candidate in a phase I/II study that included 421 adults between 60 and 89 years of age, announced in a press release on 9 September that it seems to work as well in older adults as it does in younger ones. However, a phase I study by international pharma company Pfizer and BioNTech in Mainz, Germany, showed that their vaccine BNT162b2 provokes an immune response that is about half as strong in older adults as it is in younger ones². The older adults still produced more antibodies in response to the vaccine than people of a similar age who had had COVID-19, but it’s not known how these levels translate into protection from the virus.

Most COVID-19 vaccine trials include at least some older adults. But a recent analysis of 18 such trials found that the risk of exclusion is high³. More than half had age cut-offs and many were at risk of excluding older participants for other reasons, including underlying conditions.

If COVID-19 vaccines perform less well in older adults, researchers might be able to find ways to tweak the shot itself to elicit a stronger response. Some influenza vaccines, for instance, include immune-boosting ingredients or higher doses of the viral antigen. But some scientists say there is a better option. They are developing and testing drugs that could improve how older adults respond to vaccines and might also help them fight viruses more effectively in the first place. Rather than working with the limitations of the ageing immune system, they are planning to rejuvenate it.

Forever young

Many researchers have grown old trying to pinpoint ways to reverse the ageing process. In the past decade, however, they have made serious progress in identifying particular molecular targets that might help in this quest.

One promising class of anti-ageing drug acts on pathways involved in cell growth. These drugs inhibit a protein known as mTOR. In the laboratory, inhibiting mTOR lengthens lifespan in animals from fruit flies to mice. “mTOR is one of probably multiple biologic mechanisms that contribute to why we age and why our organ systems start to decline,” says Joan Mannick, co-founder and chief medical officer of resTORbio, a biotech company based in Boston, Massachusetts, that aims to develop anti-ageing therapies.

In a study published in 2018 and carried out when Mannick was at the Novartis Research Institutes in Cambridge, Massachusetts, she and her colleagues tried damping down mTOR in elderly adults to see if this could improve immune function and lower infection rates⁴. The 264 participants received a low-dose mTOR inhibitor or a placebo for six weeks. Those who received the drug had fewer infections in the year after the study and an improved response to the flu vaccine. On the basis of her work on mTOR inhibition, Mannick, by then at resTORbio, launched a phase III trial in 2019 to see if a similar mTOR inhibitor called RTB101 could stave off respiratory illnesses in older adults.

That trial failed to show the desired effect, perhaps because infections were monitored by self-report of symptoms rather than requiring a lab test to confirm infection, as in the earlier trial. That created “a lot more noise”, says Ilaria Bellantuono, co-director of the Healthy Lifespan Institute at the University of Sheffield, UK, who was not involved in the trial. “A much bigger group would have been required to see a difference.”

Still, the data from this and an earlier trial suggested that participants who received the mTOR inhibitor had fewer severe infections from circulating coronaviruses and recovered faster from them than the placebo group. The trials pre-date the emergence of SARS-CoV-2, but they suggest that RTB101 could lessen the severity of infection. resTORbio is now testing that idea in 550 nursing-home residents aged 65 and over.

RTB101 is similar to an already approved mTOR inhibitor, the immune-suppressing drug rapamycin. At least four other groups are testing rapamycin in small numbers of infected individuals as a possible COVID-19 therapy; one group is trialling the drug exclusively in adults aged 60 or older.

The type 2 diabetes drug metformin also dampens down mTOR’s activity, albeit indirectly. Some studies suggest that people who take metformin are less likely to be hospitalized or die if they contract COVID-19. A small retrospective study in China found that the mortality among hospitalized individuals with COVID-19 taking metformin was 2.9% compared with 12.3% in people who didn’t take the drug⁵. Researchers at the University of Minnesota in Minneapolis analysed data on hospitalized individuals with COVID-19 who had an average age of 75, some of whom were already taking metformin for obesity or diabetes. They found a significant reduction in mortality among women taking metformin, but not among men⁶.

Carolyn Bramante, an obesity researcher who led the University of Minnesota study, points out that diseases such as diabetes and obesity lead to some of the same immune deficits as occur in older age. She and her colleagues plan to launch a trial of 1,500 people aged 30 and over to determine whether metformin could help stave off SARS-CoV-2 infection or prevent the worst outcomes in people already infected.

Meanwhile, Jenna Bartley, who studies ageing at the University of Connecticut in Storrs, is assessing whether metformin can boost responses to flu vaccine in a small trial of older adults. The idea, based on her work in mice, is that metformin can improve the energy metabolism of the T cells of the immune system, making them better at detecting new threats. Bartley has finished collecting data, but because her lab was shut down owing to COVID-19, she won’t have the results analysed for a few more weeks.

If metformin works against COVID-19, researchers will still have to tease out why. Kaeberlein points out that no one is quite sure how metformin works because it has so many targets. “It’s about the dirtiest of dirty drugs out there,” he says. It was originally used as an anti-influenza drug; Bramante says it helps tamp down inflammation. Aside from the mechanistic unknowns, the advantage is that metformin has been used for decades and is generally safe. Children can take it, as can pregnant women. “Metformin is a medication that you actually could give prophylactically for 12 months without having to do any follow-up,” Bramante says, “and it costs less than US$4 a month.”

Soothing balm

mTOR is a classic anti-ageing target, but it’s far from the only one. In fact, many anti-ageing pathways seem to be linked, says James Kirkland, who studies cellular ageing and disease at the Mayo Clinic in Rochester, Minnesota. “That is, if you target one, you tend to affect all the rest,” he says. Many of the immune changes that come with ageing lead to the same result: inflammation. So researchers are looking at drugs that will calm this symptom.

Arne Akbar, an immunologist at University College London, has shown that the anti-inflammatory drug losmapimod, which is being developed as a therapy for muscular dystrophy, might help boost immunity. In a 2018 study, the researchers injected chickenpox virus into the skin of elderly adults⁷. Although these people had already been exposed to chickenpox, their immune response was lacklustre, hampered by excess inflammation. When the team gave the study participants losmapimod, it ratcheted down inflammation by about 70% and improved their immune responses.

In June, the company currently developing losmapimod — Fulcrum Therapeutics in Cambridge, Massachusetts — launched a 400-person phase III study to investigate whether the drug could prevent death and respiratory failure in older people hospitalized with COVID-19.

“Senescence is really a key factor in ageing,” says Eric Verdin, president and chief executive of the Buck Institute for Research on Aging in Novato, California, who is not involved in the fisetin research. No senolytics have currently been approved for clinical treatment, however. “This is one area that has been much less studied,” he says.

Kaeberlein says it’s likely that most companies will pursue anti-ageing drugs as therapies before they test them as prophylactics. “It’s much easier to get a therapy approved in people who are already sick,” he says. He thinks that mTOR inhibitors hold the most promise. “If I had the power to go back to the beginning of this whole COVID pandemic and try one thing, I’d pick mTOR inhibitors — rapamycin specifically,” he says. According to his back-of-the-envelope calculations, if rapamycin works in the same way in people as it does in mice, it could reduce COVID-19 mortality by 90%.

Kirkland says he can envisage giving one of these anti-ageing drugs as a primer before vaccination. “We have to figure out ways to target fundamental ageing mechanisms at around the time that we’re vaccinating people,” he says, “but we have to find ways of doing this that are safe and effective.”

Added ingredients

If tweaking the immune system proves too challenging, there might be ways to juice up the vaccine itself. For flu, there are two vaccines aimed specifically at people over 65, which help worn immune systems to stage a response. One, Fluzone High-Dose, contains four times the standard amount of flu virus antigens, and the other, Fluad, relies on an immune-boosting molecule called an adjuvant.

A team led by vaccinologist Ofer Levy at Boston Children’s Hospital in Massachusetts is working on a COVID-19 vaccine specifically for older adults, using an in-vitro screening system to identify the best adjuvants. “Vaccines were typically developed as one-size-fits-all,” he says. But a lot of features — age, sex, and even the season — affect vaccine responses, Levy says. The best combinations of adjuvant and vaccine they find will be tested in mice and then in humans.

But, in general, developing medications to improve immune function seems like a much smarter strategy than creating vaccines specifically for elderly people, says Claire Chougnet, an immunologist at Cincinnati Children’s Hospital Medical Center in Ohio, who is studying inflammation in aged mice. Vaccine development is costly and time-intensive. “In the case of an emerging virus, when you want a quick response, that makes things even more complicated if you have to do two types of vaccine,” she says. Plus, individual vaccines target specific pathogens, but an immune-boosting medication could be used with any vaccine. “That could work for flu, that could work for COVID-19. That would work for COVID-25,” she says. The approach is “extremely versatile”.

Verdin agrees that supporting the older immune system should be a priority. “I think the net result of all this will be renewed interest in understanding the defect in the immune response in the elderly.” That has implications not only for the coronavirus, but also for a host of other diseases, including other viral infections and even cancer. “COVID-19 has brought to the front something that a lot of people have ignored.”

The post How anti-ageing drugs could boost COVID vaccines in older people appeared first on MyMedicPlus.

Doctors look to HIV and Ebola drugs for coronavirus cure

mymedicplus — Fri, 21 Feb 2020 07:14:50 +0000

Source: theguardian.com

Doctors are likely to know within two to three weeks whether drugs being used to treat patients infected with the new coronavirus are working, according to the World Health Organization.

The timetable for early results from two trials taking place in China is short but feasible because of the large concentration of sick people at the centre of the outbreak in Hubei province. That allows a significant number of people of similar ages, fitness and stage of illness to be compared.

The drugs have been approved for other conditions, which means they do not have to undergo safety tests in animals and then humans.

Two trials were expedited on the recommendation of the WHO’s experts. Patients in one are being given Kaletra, taken by people with HIV. The drug is a combination of two antiretrovirals, lopinavir and ritonavir. Scientists are awaiting the results from the first 200 people to be treated with it.

The other drug in trials is remdesivir, made by Gilead. It was tested during the Ebola outbreak in the Democratic Republic of the Congo in 2018 but it was not sufficiently effective against that virus.

The new trial of remdesivir will be “gold standard” and investigate how well it works in moderately and severely ill patients compared with others given a placebo.

The WHO’s director general, Dr Tedros Adhanom Ghebreyesus, said at a briefing on Thursday there would be preliminary results within three weeks. The drugs chosen have been prioritised by the organisation’s research and development experts.

A third drug, the antimalarial chloroquine, which was being used in China, was not in trials, the WHO said.

Tedros said the international team led by the WHO, now in China, was discussing with frontline workers the efficacy of various treatments. It was important to test and diagnose people promptly, he said, because “the earlier patients are tested and treated, the better they do”.

The team includes experts from several countries, including the US – despite tense Washington-Beijing relations over trade. Others are from Germany, Japan, Nigeria, Russia, South Korea and Singapore.

There are no proven therapeutics for Covid-19, the illness caused by the coronavirus, just as there were none for Sars (severe acute respiratory syndrome). Kaletra is being trialled in Mers (Middle East respiratory syndrome) but the cases are too few to get results quickly.

Tedros said the team was pushing ahead with a vaccine for the long term but it could take about 18 months.

There are 74,675 cases of Covid-19 in China and there have been 2,121 deaths. “The data from China continues to show a decline in new confirmed cases. We are encouraged by this trend but this is no time for complacency,” the WHO’s director general said. Outside China there had been 176 cases in 26 countries and seven deaths, he said.

He urged the international community to help fund the fight against the disease.

“Because of the serious measures that China is taking, the number of cases in the rest of the world is small. But it doesn’t mean that the small number of cases in the rest of the world will stay the same for long.”

The WHO issued an appeal to raise $675m (£524m) because “the finance is still low”, Tedros said.

The post Doctors look to HIV and Ebola drugs for coronavirus cure appeared first on MyMedicPlus.

Unichem, Macleods recall drugs for blood pressure, diabetes from US marketAuto Draft

mymedicplus — Mon, 17 Feb 2020 07:31:12 +0000

Source: businesstoday.in

Drug firms Unichem Pharmaceuticals and Macleods Pharma are recalling various lots of tablets used for treatment of high blood pressure and diabetes from the US market, according to a latest enforcement report of the American health regulator.

Unichem Pharmaceuticals USA Inc is recalling 1.91 crore units of Clonidine Hydrochloride tablets used for treating high blood pressure from the US market, the report said. he company is recalling units of Clonidine Hydrochloride tablets, USP 0.1 mg manufactured by Unichem Laboratories Ltd at Goa facility, it added.

The reason for the voluntary ongoing nationwide is “failed impurities/degredation specifications. This recall is initiated as a precautionary measure due to potential migration of Benzophenone at very low level into product from container label, the United States Food and Drug Administration (USFDA) said.

On the other hand, Macleods Pharma USA Inc is recalling 4,694 bottles of Pioglitazone and Metformin Hydrochloride tablets used to treat high blood sugar levels caused by type 2 diabetes from the US market. The company is recalling Pioglitazone and Metformin Hydrochloride tablets USP 15 mg/500 mg, manufactured by Macleods Pharmaceuticals Ltd at its baddi facility in Himachal Pradesh, the report said.

The reason for the voluntary nationwide ongoing recall is on account of it being “subpotent drug: out of specification assay result, below specification, for two lots of Pioglitazone And Metformin Hydrochloride tablets,” the USFDA said.

Both the recalls by the companies are class III recalls, it added. As per the USFDA, a class III recall is initiated in a “situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.

The post Unichem, Macleods recall drugs for blood pressure, diabetes from US marketAuto Draft appeared first on MyMedicPlus.

Sanofi’s sunny forecast for Dupixent and its aging diabetes drugs just might be achievable: analyst

mymedicplus — Fri, 14 Feb 2020 06:47:29 +0000

Source:fiercepharma.com

Ever since he took over as CEO of Sanofi late last year, Paul Hudson has been promising skeptical investors that the company’s hot immunology drug Dupixent could eventually hit €10 billion in annual sales. That would go a long way towards making up for Sanofi’s flagging diabetes drugs, but Wall Street analysts aren’t necessarily convinced it’s achievable.

Now, one influential Wall Street firm is making the bull case for Sanofi, declaring not only that the company’s Dupixent forecast is achievable, but that the diabetes situation isn’t as bad as it looks.

Geoffrey Porges and his colleagues at SVBLeerink peg sales of Dupixent at €3.5 billion this year and €9.1 billion in 2026. That long-term forecast is 10% to 15% higher than the consensus estimate.

It’s built on expectations for new Dupixent approvals. The med is currently approved to treat atopic dermatitis, sinusitis and asthma, but SVBLeerink’s analysts believe it has a good chance of success in a half-dozen or so other diseases, including esophagitis.

The reason for their optimism? Anecdotal reports published in the scientific literature suggest that Dupixent works in several diseases that are not yet included in the product’s label, they said. That bodes well for “multiple label expansion opportunities,” they wrote in a report to investors.

Several trials are underway and “adoption should be relatively high, provided Dupixent shows efficacy consistent with the anecdotal reports. At this stage the biology of these diseases … suggests that there is a relatively high probability of a positive outcome from these trials,” they said.

During Sanofi’s fourth-quarter earnings call last week, Hudson said that with Dupixent, “I think we have a realistic expectation to be the leading biologic in the dermatologist’s office. Likewise in allergists.” As for the future, he added “the foundation stones are very, very strong for what we are doing with Dupixent across multiple geographies, multiple indications and multiple specialty groups.”

Dupixent’s strong 2019 growth—sales jumped 151% to €2.1 billion for the year—came amid declining sales of Sanofi’s diabetes products. Revenues for the diabetes franchise fell 8% to €5.1 billion.

In fact, Sanofi’s diabetes sales grew reliably until 2015, but they’ve been falling every year since, SVBLeerink pointed out in a second report to investors. Much of the decline was attributed to biosimilar competition from Eli Lilly, which has cut into Sanofi’s dominance in the long-acting insulin market. Sales of Sanofi’s Lantus have been cut in half by Lilly’s rival Basaglar.

Still, SVBLeerink predicts that the decline of Sanofi’s diabetes business will stabilize starting in 2021, thanks to Toujeo, its ultra-long-lasting insulin product. Sales of Toujeo grew 3% to €883 million last year. The analysts expect sales of the product will increase to €1.2 billion in 2023.

“Our estimates and confidence in the [diabetes] business unit’s stabilization are based on flattening market share loss, moderating price declines, and ex-US revenue growth,” they wrote.

Earlier this week, Sanofi followed up on its fourth-quarter report by shaking up its top management ranks, shrinking the executive committee from 14 to 10 people. The change included separating the roles of chief medical officer and chief digital officer, both of which were held by Ameet Nathwani. He was among the executives who headed for the exits.

Hudson said during the fourth-quarter conference call that boosting the role of chief digital officer would help the company “improve our user experience and data science management internally.” He admitted Sanofi has been slow to embrace technologies like AI in drug discovery and development.

Whether all these changes will help Sanofi reach its lofty goals for Dupixent remains to be seen. There are plenty of obstacles, including brewing competition from more than 20 immunology drugs in the pipeline. Nevertheless, SVBLeerink said, “Dupixent is the brightest spot in an otherwise fairly lackluster pipeline and portfolio.”

The post Sanofi’s sunny forecast for Dupixent and its aging diabetes drugs just might be achievable: analyst appeared first on MyMedicPlus.

Up to 150,000 Irish blood pressure patients ‘may not need drugs’

mymedicplus — Wed, 29 Jan 2020 05:23:05 +0000

Source: irishtimes.com

Up to 150,000 Irish blood pressure patients may not need additional drug treatment despite new guidelines suggesting they do, according to new research.

The study by the National Institute for Prevention and Cardiovascular Health (NIPC) in Galway and the National University of Ireland Galway calls into question the validity of recent changes to treatment recommendations for up to a quarter of the 600,000 Irish people who are being treated for high blood pressure.

US and European guidelines for treating hypertension were recently changed in that high blood pressure was redefined as 130/80, instead of the previous level of 140/90.

As a result, as many as 150,000 patients with a bottom blood pressure number of over 80, but a normal top blood pressure number below 130, are potentially at risk of being overtreated, according to the US-Irish research.

This is because the study found that this specific type of blood pressure pattern does not appear to be adversely affecting their health.

Blood pressure levels are denoted by two numbers, with the top number known as the systolic, and the bottom number as the diastolic reading. The top number records blood pressure when the pressure is at its highest, ie when the heart muscle squeezes out the blood. The bottom number is when the heart relaxes and allows the blood to flow back into the heart.

The study, published in the Journal of the American Medical Association, found the recommendation to lower the diastolic threshold for hypertension from 90 to 80 was based on expert opinion – a relatively weak type of evidence – not on results from clinical trials.

Target

Prof J William McEvoy, medical and research director of the NIPC, said despite differences between them in the definition of high blood pressure, US and European guidelines both recommend the target of 130/80 be achieved for those receiving treatment to lower their blood pressure.

As a result, their doctors could be aiming to get the diastolic (lower) number to less than 80 despite the patient having a normal systolic (top) blood pressure of below 130.

“This is a concern, because our team found no adverse health outcomes from a diagnosis of isolated diastolic hypertension [normal top number but higher bottom number] when the new guideline criteria are used.

“The absence of negative health outcomes in this group challenges the need to intensify the blood pressure treatment of these adults with higher diastolic blood pressure. Instead the main focus should be on getting the top number [systolic blood pressure] under control.”

High blood pressure, which usually has no symptoms, is regarded as a major risk factor for heart disease and stroke.

The post Up to 150,000 Irish blood pressure patients ‘may not need drugs’ appeared first on MyMedicPlus.

HIV patients lose immunity to smallpox despite vaccination, AIDS drugs: Study

mymedicplus — Mon, 06 Jan 2020 05:21:52 +0000

Source: indianexpress.com

People infected with the Human Immunodeficiency Virus (HIV) lose immunity to smallpox even after much of their immune system is restored with drug therapy, according to a study which may lead to new interventions against opportunistic infections in HIV patients.

According to the researchers, including those from Oregon Health & Science University in the US, this condition called HIV-associated immune amnesia may explain why patients with AIDS tend to have shorter lives on average than their HIV-negative counterparts despite being on drug therapy.

The study, published in the Journal of Infectious Diseases, compared the immune system’s T-cell, and antibody responses of a total of 100 HIV-positive and HIV-negative women who were vaccinated against smallpox in their youth.

Based on the findings, the researchers said the immune systems of HIV-positive women who were on antiretroviral drug therapy had a limited response when their blood was exposed to the ‘vaccina virus’ used in the smallpox vaccine.

They said those vaccinated against smallpox, normally have CD4 T cells that remember the virus and respond in large numbers when they’re exposed again. Earlier studies had revealed that the these immune cells specific to the smallpox virus are maintained for up to 75 years after vaccination. But in the current study, despite antiretroviral therapy boosting CD4 T cell counts in HIV-positive patients, they were susceptible to smallpox infection.

According to the scientists, this indicates that while antiretroviral therapy may boost total T cell counts overall, it doesn’t recover virus-specific T cells generated from prior childhood vaccinations.

The research team plans to evaluate whether the same findings apply for HIV-infected men, and if people living with HIV also lose immune memory to other diseases.

The post HIV patients lose immunity to smallpox despite vaccination, AIDS drugs: Study appeared first on MyMedicPlus.

AIDS gains risk slipping away

mymedicplus — Thu, 24 Oct 2019 06:02:00 +0000

Source: politico.eu

HIV/AIDS has gone from a mysterious deadly illness to a manageable chronic disease. But a lot happened in the roughly four decades it took to get there. And, according to the American activist David Barr, there’s much that needs to be done to ensure the gains are not reversed.

Barr has seen almost everything in his 35 years of fighting the epidemic, from the early gatherings in the 1980s of the pioneering activist group ACT UP to the roll-out of treatments that saved millions of lives, including his own.

Looking back at his life’s work, and the seminal efforts in the United States that helped launch a global movement, Barr broke down the six stages of the battle against HIV/AIDS.

Fear

To be gay in the 1980s was to be scared. There was a disease infecting your friends, and someday it might come for you, too — if it hadn’t already.

Lawyers around the U.S. were calling the Lambda Legal Defense Fund, where Barr was working, asking what they could do for clients who had been kicked out of doctor’s offices, thrown out of apartments, or fired.

There wasn’t much they could do. By 1985, the U.S. government had just licensed an antibody test that screened for HIV, the precursor to AIDS, which had already claimed thousands of lives in the U.S.

Lambda was advising the gay community not to take the test because there was nothing protecting people should they test positive. Texas had tried, after all, to pass a law forcing those who tested positive to be quarantined.

And what were you supposed to do if you tested positive anyway? That just meant you were afflicted by an illness for which there was no cure.

“And in the midst of all of it, our government wasn’t responding at all,” Barr said.

So the gay community developed their own legal responses, introduced education about how to keep from catching the disease, and put in place social work services. And they began to fight back.

Fight

In New York City in the late 1980s, Monday nights at the newly established AIDS Coalition to Unleash Power (ACT UP) meetings were the place to be. By the summer of 1987, hundreds of gay people made their way to take part.

“People were sick and dying all around us, constantly,” Barr said. “It felt like we were in a war zone.”

In a politically charged time, ACT UP was the angry activist group. Their first action was to protest the high price for the antiretroviral azidothymidine (AZT), the only treatment on the market for people living with HIV.

In October 1988, ACT UP took the fight to the U.S. Food and Drug Administration in suburban Maryland, donning lab coats with their hands painted red with fake blood, demanding a government response. They wanted more studies on HIV/AIDS, and they wanted quicker access to possible treatments.

“That was really the demonstration where the national AIDS movement was born,” Barr said.

Drugs

As the camaraderie of the early years began to fray, Barr and other members of ACT UP broke off in 1991 to form their own group, Treatment Action Group (TAG), to begin a new phase of activism. Rather than fight the power, they’d try to harness it. “I didn’t need to take over the FDA,” Barr explained. “I needed to get into the room with FDA.”

In 1993, AIDS claimed around 40,000 lives in the U.S. alone.

That year, Barr and four other members of TAG protested a conference in Berlin, where a doctor planned to say that taking AZT and two other analogs, ddI or ddC, was effective for a particular group of people. Barr and his fellow activists stormed in to tell the crowd that her results were skewed, and the drugs were actually not effective at all. The group of five marched out to applause and the feeling of triumph.

“We had made our point,” he said.

But later, as they sat in a park, the reality of what that meant hit them: They were left without a cure. “We were the ones who were going to suffer from this,” he explained.

Turning point

The mid-1990s were a time of guarded optimism. Patients who had signed up for clinical trials and an expanded access program were taking what was informally known as the AIDS cocktail, and it seemed to be working: “People getting up from their deathbeds — literally,” Barr said.

The pills were difficult to take. Patients couldn’t miss a dose. The side effects could be harsh. But they were working. By 1996, antiretrovirals were available on the market for anyone with the virus — not just those in the expanded trials. The FDA, having recognized the urgency, was flagging new treatments for approval, with less data than was needed for any other group of drugs before it. That was the first year that death rates began to decline.

“There was certainly some elation,” Barr said. “But there was also this odd guilt, because why am I alive, and my friends aren’t? How did I get lucky, and they didn’t? There was no rhyme or reason to any of it.”

Global battle

The fight against HIV/AIDS went worldwide in the 2000s.

The momentum began at the XIII International AIDS Conference in Durban, South Africa in 2000, when activists in the country took their national fight to the global stage.

The Global Fund and the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the two main revenue streams for HIV/AIDS funding, were put in place. The World Health Organization set a goal of getting 3 million people into treatment by 2005 — “a very ambitious target at the time.”

HIV/AIDS activists teamed up around the world. Some faced “much greater challenges” than in New York, and their collaborative work built momentum and help rake in money.

“We were making the right argument at the right time,” Barr said.

Fragile success

Barr says the fight has only gotten more difficult. Funding for HIV/AIDS has remained relatively flat. A 2019 report from the Kaiser Family Foundation and UNAIDS found that donor governments’ spending hasn’t changed much in the last year. Donors are also less inclined to give money for HIV-specific work.

Meanwhile, the number of people living with HIV continues to rise. “Every year you have a flat budget it’s like a cut,” Barr said.

U.N. member states signed up to 90-90-90 targets in 2014, pledging to ensure that by 2020, 90 percent of people with HIV will know their status, 90 percent of those diagnosed will be on antiretroviral therapies, and 90 percent of those receiving therapy will have succeeded in repressing the virus. But they have not come up with the money to make that happen.

Barr objects to how UNAIDS and PEPFAR frame their messaging. They claim “we’ll meet the targets, and we’ll end AIDS,” he said. “That’s not true.” Those starting treatment now will have to maintain it for decades. “Those bills are going to keep coming in,” he said.

Then there’s sex and drugs — as the fear subsides, a whole new generation is growing up now who has not learned the lessons from the 1980s and 1990s.

“The success we have made is remarkable,” Barr said, “but it’s incredibly fragile.”

“If the response is not sustained and maintained, we’re going to lose the tools we’ve miraculously been able to develop [over the decades],” Barr warned. “And then we’re back to 1986.”

The post AIDS gains risk slipping away appeared first on MyMedicPlus.

Anti-Aging Drugs Could Be On The Market In The Next 5 Years

mymedicplus — Sat, 07 Sep 2019 07:17:03 +0000

Source: worldhealth.net

In the interview he explains how a simple treatment may one day be able to delay the aging process and all of the ailments that are associated with it, this may even be available within as little as 5-12 years. Expert on the aging process and age related conditions, Dr. Wilson, says that trials involving senolytics have been successful in animals to make them live longer. The upcoming human clinical trials may not be able to stop the aging process, but it is going to interfere with them.

Senolytic drugs interfere with zombie senescent cells in the body that accumulate over time and are harmful. “The senescent cells are kind of ornery – they reach the end of their working life, they stop functioning, and instead of allowing themselves to be digested and disposed of, they sit around, release factors and produce inflammation, so they may represent five or 10 or 15 percent of the cells of a particular tissue, but they’re all the ones that cause all the trouble,” explains Wilson.

“So in the last two or three years, people have been investigating what happens if you get rid of the senescent cells – and there are medications and chemicals that are around today – that appear selectively to knock them off.” he adds. Mice studies have shown killing off these zombie cells results in significant improvements.

Medications or chemicals are currently being used for other purposes that appear to have the ability to be “selectively knocking off the senescent cells, and people are doing that and now they’re trying clinical studies … and they seem to be getting some clinical improvement, but whether that’s going to translate into a broader extension remains to be seen”.

“The important aspect of this is that there are other chemicals, other medications out there which are already being investigated for their impact on slowing down ageing, and the reason why slowing down ageing is important is we have a number of diseases that are closely associated with ageing – dementia, diabetes, heart stroke, cancer, Parkinson’s disease – and the thought is if you can slow down the ageing process, can you benefit each of these diseases and turn them into something that can be now managed far better than before. “If you can improve the healthspan of those folk by intervening – and if one drug will treat the multiple diseases – then that’s a great outcome.” says Wilson.

There are positive and negative outcomes in people having extended healthspans. “It may be that a number of these other drugs in use targeting different things, some senescent cells, and one drug is showing that you can improve the immunity against infections in older individuals – older people – and you can, in fact, boost their response to vaccination, and at the same time, if you can reduce their resistance to getting pneumonia, then you’re improving their healthspan from that sort of perspective … but the question we do have is a social question. Our demographics are changing so fast that it’s almost unbelievable,” he said. One extreme example is Japan, where the number of centenarians jumped from 120 in the early 1960s to 70,000 last year.”

Simply having a pill to kill off these zombie cells maybe able to improve healthspan, but it must be paired with a healthy lifestyle which includes following a healthy balanced diet, regular exercise, and maintain good in person relationships. “All those things are important, because our ageing starts to plug in early on, so our cells are programmed, we age.”

According to Wilson one who is in their 30s is already “10 years past your peak for some things, like computer games … so already, parts of your physiology is starting to decay a little, so that means, in fact, all the activities you’ve suggested – before exercise, diet and all of that – do play a part, and the earlier you bring those things into play, the more likely you are to extend the healthspan”.

Most are afraid to age “because they lose control, they lose independence, and they lose relevance, and losing relevance becomes kind of tricky. The most powerful indicator or activity that can improve our long-term healthspan and outcome are personal relationships – social relationships are important but personal relationships between, say, a spouse or a partner or close friends – have greater impact in terms of feeling better, looking positive about life, feeling happier and having a better outcome. These social interventions – the psychological way we approach this – becomes very important.”

The post Anti-Aging Drugs Could Be On The Market In The Next 5 Years appeared first on MyMedicPlus.

‘Puberty is not a disease’: Italian council moves to ban gender-bending drugs for kids

mymedicplus — Wed, 24 Jul 2019 10:47:40 +0000

Source: lifesitenews.com

TRIESTE, Italy, July 23, 2019 (LifeSiteNews) — The regional council of Friuli Venezia Giulia, an autonomous region in northeastern Italy, approved a motion calling on the national government to prohibit so-called puberty-blocking drugs used in so-called reassignment treatment for gender-confused children.

In a July 17 move by a center-right majority led by the League party, the Friuli Venezia Giulia regional council approved a motion calling on Italy’s national government to prohibit the prescription of drugs that prevent normal sexual development of adolescents.

The League’s leader is Deputy Prime Minister Matteo Salvini, who is one of the three members in Italy’s coalition government that includes Deputy Prime Minister Luigi Di Maio of the Five Star Party (M5S) and Prime Minister Giuseppe Conte. The leftist parties in the regional council, including M5S, voted against the motion.

According to the council’s motion, “puberty is not a disease” and thus should not be prevented with surgery and medications that can produce irreversible effects. It also noted the long-term negative effects of drugs containing triptorelin.

“There is no evidence, in fact,” reads the motion, “on the effective full restoration of fertility in the case of withdrawal from treatment.” It cites data circulated by the American College of Pediatricians, which stated that as many as 98% of minors will outgrow their gender dysphoria (a feeling that one’s biological sex does not accord with one’s gender expression) after having passed through puberty naturally.

“We express opposition to the use of this drug,” said Mauro Bordin, according to VoceControCorrente. Bordin, who represents the League on the council and was a signatory of the motion, went on to say there are not enough clinical studies, “especially regarding the possible long-term negative effects and why blocking puberty pharmacologically could cause a misalignment in [adolescent] physical and cognitive development.” He said puberty-blockers could even compromise those parts of the brain that contribute to the definition of sexual identity, which also involve both environmental and educational factors.

Bordin said the motion is not an “ideological position, but a proposal of common sense in the exclusive interest of the health of children throughout Italy.” Critics have long warned against medical interventions for persons experiencing gender dysphoria. For example, Dr. Michelle Cretella of the American College of Pediatricians said in 2017, “Transgenderism is a psychological disorder, not a biological one.” She added, “Consequently, we expect transgenderism and its associated medical procedures to increase as society increasingly promotes this lifestyle.” Regarding a move by the American Society of Plastic Surgeons to coin the term “gender confirmation surgery,” she said, “Linguistic engineering precedes and accompanies social engineering.” Cretella went on to say, “Transgender activist physicians realize that sex reassignment surgery is a misnomer. In other words, surgery cannot change a person’s sex. By renaming sex reassignment surgery gender confirming surgery, they give the impression that they are affirming an inborn trait and further the innate immutable transgender myth.”

On the Italian Notizie Pro-Vita website, pro-life activist Dr. Silvana De Mari said, “The body is real. The mind must accept this reality and love it.” According to De Mari, “where there is no harmony between mind and body, the mind must be cured; the body must not be altered. The concept that sees the body and mind as disconnected,” said De Mari, is a pathological dissociative disorder.

The American College of Pediatricians recently warned the surgeon general of the United States against surgical and hormonal methods to obscure the sex of minors. ACP pointed to warnings issued by the U.K.’s Royal College of General Practitioners that the long-term effects of these techniques have not been subjected to sufficient research.

Triptorelin is marketed by the France-based Ipsen as Decapeptyl and as Diphereline and Gonapeptyl by Ferring Pharmaceuticals of Switzerland. In the United States, it is sold by Watson Pharmaceuticals as Trelstar. Triptorelin is a synthetic version of the natural hormone GnRH, which regulates the release of gonadotropins that are involved in the development of release of ova from human ovaries. Among the side effects, for women and girls, is ovary over-production; ovarian cysts; miscarriage; and heavy, prolonged menstruation. It is used for suppressing puberty.

The post ‘Puberty is not a disease’: Italian council moves to ban gender-bending drugs for kids appeared first on MyMedicPlus.